Source: EURLEX
Language: en
Format: md

Judgment of the General Court (Second Chamber) of 15 September 2017 — Viridis Pharmaceutical v EUIPO — Hecht-Pharma (Boswelan)

(Case T‑276/16)

(EU trade mark — Revocation proceedings — EU word mark Boswelan — Declaration of revocation — Article 51(1)(a) of Regulation (EC) No 207/2009 — Absence of genuine use of a trade mark — No proper reasons for non-use)

| 1. | EU trade mark—Surrender, revocation and invalidity—Causes of revocation—Absence of genuine use of a trade mark—Proof of use of the earlier mark—Genuine use—Meaning—Criteria for assessment  (Council Regulation No 207/2009, Art. 51(1)(a))  (see paras 30-33) |

| 2. | EU trade mark—Surrender, revocation and invalidity—Causes of revocation—Absence of genuine use of a trade mark—Word mark Boswelan |

| 3. | (Council Regulation No 207/2009, Art. 51(1)(a))  (see paras 35, 36, 38-40, 59-61, 63) |

| 4. | EU trade mark—Surrender, revocation and invalidity—Causes of revocation—Absence of genuine use of a trade mark—Concept of ‘proper reasons’ for non-use—Independent and uniform interpretation—Obstacles bearing a direct relation to the trade mark rendering its use unreasonable or impossible and independent of the volition of the trade mark proprietor  (Council Regulation No 207/2009, Art. 51(1)(a))  (see paras 52, 54) |

| 5. | EU trade mark—Decisions of the Office—Legality—Examination by the EU judicature—Criteria  (Council Regulation No 207/2009)  (see paras 62) |

| 6. | EU law—Principles—Protection of legitimate expectations—Conditions—Specific assurances given by the authorities  (see paras 67, 68) |

Re:

ACTION against the decision of the Fifth Board of EUIPO of 29 February 2016 (Case R 2837/2014-5), relating to revocation proceedings between Hecht-Pharma and Viridis Pharmaceutical.

Operative part

The Court:

| 1. | Dismisses the action; |

| 2. | Orders Viridis Pharmaceutical Ltd to pay the costs. |

[Top](#document1)